Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years
Novartis’ experimental drug del-desiran failed to meet its primary goal in a late-stage myotonic dystrophy type 1 trial, sending NVS shares down about 10% on Sept. 8, 2026 and wiping out roughly 24 billion Swiss francs (about $29.6 billion) in market value.
Sep 18, 2026 ·
Yahoo Finance


















